top of page

Using NK cell therapies for autoimmune disease and cancer with Artiva's CEO

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page